Trial reportJournal of anesthesia2018
Evaluation of pharmacokinetic models of intravenous dexmedetomidine in sedated patients under spinal anesthesia.
Trial report in Journal of anesthesia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The predictive performance of the Marsh model for propofol target-controlled infusion during laparoscopic surgery with liver retraction.Journal of anesthesia · 2026Article
- Target controlled infusion in the intensive care unit: a scoping review.Journal of clinical monitoring and computing · 2026Article
- General Purpose Pharmacokinetic-Pharmacodynamic Models for Target-Controlled Infusion of Anaesthetic Drugs: A Narrative Review.Journal of clinical medicine · 2022Review
- Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!Journal of anesthesia · 2020Article
- Dexmedetomidine as an adjuvant during general anesthesia.Journal of anesthesia · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLittle information is available on the predictive ability of previously published pharmacokinetic models of dexmedetomidine in patients under spinal anesthesia. We evaluated nine published pharmacokinetic models that were constructed in different study settings.
methodsSixteen patients received dexmedetomidine infusions after spinal anesthesia according to the manufacturer's recommended regimen (6 µg/kg/h over 10 min followed by 0.2-0.7 µg/kg/h) or target-controlled infusion (initial target of 1.5 ng/ml using the Dyck model). Dexmedetomidine concentrations were measured and median performance error (MDPE), median absolute performance error (MDAPE), and wobble were calculated.
resultsA total of 84 blood samples were analyzed. The pharmacokinetic model reported by Hannivoort et al. had the greatest ability to predict dexmedetomidine concentrations (MDPE 5.6%, MDAPE 18.1%, and wobble 6.2%).
conclusionsHannivoort et al.'s pharmacokinetic model, constructed with a dataset obtained from healthy volunteers, can predict dexmedetomidine concentrations best during continuous infusion under spinal anesthesia.
Indexed as
Identifiers
29098392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.